-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
This product is an innovative traditional Chinese medicine developed on the basis of clinical experience.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
This product is an innovative traditional Chinese medicine developed on the basis of clinical experience.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
.
Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
is the holder of the marketing license for the drug
.
This product is an innovative traditional Chinese medicine developed on the basis of clinical experience.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
A multi-center, randomized, double-blind, placebo/positive drug parallel controlled clinical trial has been carried out.
The results show that it can be used for the treatment of exogenous wind-heat common cold
.
